MDC Annual Neuromuscular ‘Seed Grant’ Competition Launch
MDC is very excited to announce that their Annual Neuromuscular ‘Seed Grant’ Competition has launched and are now accepting applications until Feb 2, 2021 for Translational Science Seed Grants and Clinical Health Management Grants.
During a time when health research funding is challenged due to the COVID-19 pandemic and as many like-minded organizations/agencies have had to cancel their research competitions, MDC are very grateful that they are able to continue the momentum achieved over the last several years and provide critical research funds to help accelerate the understanding of neuromuscular disorders, identify pathways for future therapies and optimize care to improve the quality of life for Canadians affected by neuromuscular disorders
For information on the scope and guidelines of this year’s competition, please visit:
https://muscle.ca/researchers/funding-guideline-deadlines/
Applications with cross-cutting applicability to multiple neuromuscular disorders under MDC’s umbrella as well as disorder-specific ones are welcomed. Special consideration will be given to relevant meritorious applications in the following disease-specific areas, through designated funds generously provided by donors: Myotonic Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Immune-mediated Myopathies, Charcot-Marie-Tooth Disease, Pediatric Neuromuscular Disorders.
The total budget per project is $60,000 for 2 years.
Key Dates:
Full Application Deadline: February 2 at 11:59 pm (EST)
Notice of Decision: April 2020
Funding Start Date: May 1, 2020
All applications are available online at proposalCENTRAL.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.